Retrophin, Inc. is turning to business development to build its rare disease-focused pipeline about a year after a Phase III failure threw its plans into disarray – the biotech has agreed to pay $90m up front with significant earnout potential to acquire privately held Orphan Technologies Ltd. and its enzyme replacement therapy candidate for homocystinuria (HCU).
The deal announced 22 October is expected to close before the end of 2020 and brings Retrophin Phase I/II OT-58,...








